EB66® partnered veterinary programs
cell line is widely used by the animal health industry all over the world.
Contributing to this success is the completion of numerous commercial and/or research agreements for the use of EB66®
cells in the production of veterinary vaccines against various viral diseases.
Three marketing authorizations have already been granted by regulatory authorities worlwide:
- In May 2014, the European Medicines Agency (EMA) granted the first ever marketing approval in Europe for a vaccine produced in the EB66® cell line for the prevention of Muscovy Duck Parvovirus (MDPV).
- Mid-March 2014, Lima-based biopharmaceutical company FARVET SAC announced the approval and launch in South America of an EB66®-based vaccine for the prevention of inclusion body hepatitis virus (IBH).
- In October 2012, the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) received a marketing authorization from the Japanese Ministry of Agriculture, Forestry and Fisheries for an EB66®-based prophylactic vaccine against Egg Drop Syndrome (EDS).